Moreover, 10 μM enzalutamide is a routinely employed dosage in pre-clinical models, both cell culture40 and in vivo studies41, of prostate cancer for evaluation of its efficacy in combination with other non-AR targeted genome therapies41–43. This evidence concerns the gene AR and prostate carcinoma.